Osmolex ER (Amantadine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 23, 2022 Category: Drugs & Pharmacology Source Type: news

Strides Pharma arm gets USFDA nod to market Amantadine Hydrochloride Softgel Capsules in America
Strides Pharma Global Pte Ltd Singapore has received approval from the US Food and Drug Administration (USFDA) for the medication, the company said in a statement. The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Symmetrel Capsules, 100 mg, of Endo Pharmaceuticals, Inc (Endo). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 21, 2022 Category: Pharmaceuticals Source Type: news

Alembic Pharma gets USFDA nod for anti-viral drug
Quoting IQVIA data, Alembic Pharma said Amantadine Hydrochloride Tablets, 100 mg have an estimated market size of USD 13 million for twelve months ending June, 2020. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 16, 2020 Category: Pharmaceuticals Source Type: news

Apace Packaging LLC Issues Voluntary Nationwide Recall of Cyclobenzaprine HCL and Amantadine HCL (Lot 16710) Due to Potential Mislabeling
Apace Packaging LLC is voluntarily recalling one lot of Cyclobenzaprine HCl Tablet, USP 5 mg 50ct Unit Dose, NDC# 50268-190-15, Lot Number 16710 and one lot of Amantadine HCl Capsule, USP 100 mg 50ct Unit Dose NDC# 50268-069-15, Lot Number 16710 to the Retail level. These products have been recalled due to a potential mislabeling. A small number of cartons containing Cyclobenzaprine HCl Tablets 5 mg UD Blister Cards may potentially be mislabeled as Amantadine HCl Capsules, USP 100 mg. The unit dose blisters inside the carton are correctly labeled as Cyclobenzaprine HCl Tablet, USP 5 mg. (Source: FDA Center for Drug Evaluat...
Source: FDA Center for Drug Evaluation and Research - What's New - May 22, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

amantadine (Symmetrel - Discontinued)
Title: amantadine (Symmetrel - Discontinued)Category: MedicationsCreated: 12/14/1998 12:00:00 AMLast Editorial Review: 8/6/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - August 6, 2019 Category: Drugs & Pharmacology Source Type: news

What are the side effects of amantadine?
This article takes a close look at the side effects of amantadine, which can range from mild to severe. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - July 3, 2019 Category: Neurology Tags: Parkinson's Disease Source Type: news

Medical News Today: What are the side effects of amantadine?
This article takes a close look at the side effects of amantadine, which can range from mild to severe. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2019 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news

Amantadine did not positively impact cognition in chronic traumatic brain injury: a multi-site, randomized, controlled trial - Hammond F, Sherer M, Malec JF, Zafonte RD, Dikmen S, Bogner JA, Bell K, Barber J, Temkin N.
Despite limited evidence to support the use of amantadine to enhance cognitive function after traumatic brain injury, the clinical use for this purpose is highly prevalent and is often based on inferred belief systems. The purpose of this study was to asse... (Source: SafetyLit)
Source: SafetyLit - May 14, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Osmolex ER (Amantadine) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 2, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Extended-Release Amantadine (Osmolex ER) for Parkinson's FDA OKs Extended-Release Amantadine (Osmolex ER) for Parkinson's
Osmolex ER tablets, taken once daily in the morning, are a proprietary formulation containing immediate- and extended-release amantadine.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 20, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson ’s Disease and Drug-Induced Extrapyramidal Reactions
BRIDGEWATER, N.J., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceutical US LLC ( “Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous system (CNS) treatments utilizing its... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 19, 2018 Category: Drugs & Pharmacology Source Type: news

Jubilant Pharma gets USFDA nod for Symmetrel's generic version
The approved drug, generic version of Symmetrel of Endo, is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 9, 2018 Category: Pharmaceuticals Source Type: news

Combination Antivirals Have Mixed Results in Treating Influenza (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH A combination of amantadine, oseltamivir, and ribavirin is associated with reduced viral load in influenza but no clinical improvement over oseltamivir monotherapy, according to a phase … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 25, 2017 Category: Primary Care Source Type: news

Potential impact of amantadine on aggression in chronic traumatic brain injury - Hammond FM, Malec JF, Zafonte RD, Sherer M, Bogner J, Dikmen S, Whitney MP, Bell KR, Perkins SM, Moser EA.
OBJECTIVE: To assess the effects of amantadine on anger and aggression among individuals with a chronic traumatic brain injury (TBI). METHODS: A cohort of 118 persons with chronic TBI (>6 months postinjury) and moderate-severe aggression selected f... (Source: SafetyLit)
Source: SafetyLit - September 15, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Gocovri (Amantadine Extended Release Capsules, for Oral Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 13, 2017 Category: Drugs & Pharmacology Source Type: news